We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 412

Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the


ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct
  • King & Wood Mallesons
  • Australia
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend


Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd


Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper


Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its


ACCC pursues Pfizer over Lipitor drug
  • HopgoodGanim
  • Australia
  • September 2 2014

Click here to view the video


Federal government’s “action plan” for Australia will the direct selling sector be affected?
  • Addisons
  • Australia
  • December 2 2014

In November 2014 the Australia federal government released its Industry Innovation and Competitiveness Agenda (the Agenda), a report1 outlining the


ACCC v Pfizer judgment summary and ramifications
  • Piper Alderman
  • Australia
  • February 27 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian


ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused


Interim authorisation granted to eRx script
  • Gilbert + Tobin
  • Australia
  • February 28 2013

The ACCC granted interim authorisation to eRx Script Exchange to allow it to enter into a contract with MediSecure to facilitate interoperability